Derek J. Maetzold Sells 1,947 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 1,947 shares of the company’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the completion of the transaction, the insider now owns 65,418 shares in the company, valued at approximately $1,331,256.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $19.20 on Friday. The business has a fifty day moving average price of $21.62 and a 200-day moving average price of $19.82. The firm has a market capitalization of $527.04 million, a P/E ratio of -8.89 and a beta of 0.93. Castle Biosciences, Inc. has a one year low of $9.26 and a one year high of $26.70.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 26.15% and a negative return on equity of 14.92%. The firm had revenue of $66.12 million during the quarter, compared to the consensus estimate of $51.32 million. Sell-side analysts expect that Castle Biosciences, Inc. will post -2.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on CSTL shares. Scotiabank boosted their target price on Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a research note on Friday, March 1st. KeyCorp boosted their price objective on Castle Biosciences from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, March 1st.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CSTL. Deerfield Management Company L.P. Series C bought a new position in shares of Castle Biosciences in the 3rd quarter worth $15,988,000. Millennium Management LLC increased its stake in Castle Biosciences by 230.9% in the second quarter. Millennium Management LLC now owns 902,089 shares of the company’s stock valued at $19,801,000 after acquiring an additional 629,448 shares during the last quarter. Bellevue Group AG purchased a new stake in Castle Biosciences during the first quarter valued at about $27,258,000. Citadel Advisors LLC lifted its stake in Castle Biosciences by 237.2% during the second quarter. Citadel Advisors LLC now owns 630,596 shares of the company’s stock worth $13,841,000 after purchasing an additional 443,589 shares during the last quarter. Finally, Wasatch Advisors Inc. boosted its holdings in shares of Castle Biosciences by 10.5% in the 1st quarter. Wasatch Advisors Inc. now owns 3,443,847 shares of the company’s stock worth $154,491,000 after purchasing an additional 327,359 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.